The purpose of this study is to examine the use of a new investigational medication for the
treatment of moderate plaque-type psoriasis. The study medication is rimegepant, an orally
administered small molecule competitive inhibitor of the calcitonin gene-related peptide
(CGRP) receptor. This medication, rimegepant, has been approved by the FDA under the trade
name Nurtec for the treatment of acute migraine. However, rimegepant has not been studied in
the treatment of moderate plaque-type psoriasis and is investigational for this indication.
The purpose of this study is to examine the use of a new investigational medication for the
treatment of moderate plaque-type psoriasis. The study medication is rimegepant, an orally
administered small molecule competitive inhibitor of the calcitonin gene-related peptide
(CGRP) receptor. This medication, rimegepant, has been approved by the FDA under the trade
name Nurtec for the treatment of acute migraine. However, rimegepant has not been studied in
the treatment of moderate plaque-type psoriasis and is investigational for this indication.
An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute
Recruiting
Antonios Likourezos
Phase 4
2021-04-22
Headaches affect over 50% of patients annually, with close to 4% of ED visits for headache.
Most headaches managed in the ED are benign, with 90% of these headaches classified as
tension, migraine, or cluster. At present, the satisfaction with ED treatment of headache is
low, and despite the multitude of available medications, the evidence- based treatment
options are often quite limited. There are over twenty different types of medications
available to the ED clinicians for managing headache, many with different routes of
administration (parenteral, intranasal, subcutaneous, and oral). Many of these medications
are provided in so-called "headache cocktail", which varies based on the physician,
institution, and patient preferences.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
